Users Stopping Weight-Loss Medications Put On Pounds at a Quadrupled Rate Than Those on Conventional Diets

New research suggests that patients who come off blockbuster weight-loss injections like Wegovy and Mounjaro can put back on lost weight at a significantly accelerated pace than those who stop conventional lifestyle regimens.

Published data in a major medical journal shows that while overweight people often shed substantial amounts of their total mass while using the jabs, the weight returns at an average rate of 0.8 kg per month upon discontinuation.

"People buying these treatments should be aware of the risk of rapid rebound weight gain when the treatment concludes," warns expert Dr. Susan Jebb.

That rate of regain implies a return to pre-treatment weight within about a year and a half.

Analyzing Therapies

The analysis, which reviewed dozens of studies involving thousands of participants, compared the outcomes of the injectable medications with other pills.

Scientists note that people who lose weight through diet and exercise usually experience a less rapid creep back—around 100 grams monthly—post-intervention.

Understanding the Rapid Rebound

Nutrition scientists propose the mode of action of the drugs accounts for the amplified rebound.

These medications mimic a natural hormone called GLP-1, which helps regulate feelings of fullness.

"Artificially providing the hormone concentrations far above than the body's typical production might result in the body to produce less of its own natural GLP-1, and could lessen responsiveness to its actions," said Dr. Adam Collins, a nutrition researcher.

"Discontinuation of this medication leads to hunger is no longer kept in check, making overeating a significant risk."

A Lifelong Issue?

Health authorities recommend the jabs for individuals with weight-linked medical conditions, accompanied by recommended diet and exercise modifications.

A number of clinicians contend that, considering the significant potential of weight regain, the treatment should be considered ongoing.

This view is supported by drug manufacturers, who state that the findings "highlight the chronic character of obesity," similar to managing conditions like diabetes.

User Accounts

People who have stopped the medication explain a sudden resurgence of appetite.

"It felt as if a switch that goes on and I was suddenly ravenous," recalled an individual.

This difficulty is compounded if individuals have not adopted lasting dietary or behavioural changes during therapy.

Growing Adoption

Figures indicate that a significant number of adults in the UK have tried these injections in the past year, with desire continuing to grow.

• Use is higher among women than men.
• The 40s and 50s age group shows the greatest usage rates.
• A large proportion obtain the drugs through private healthcare rather than the NHS.

Ultimately, clinicians emphasize that while the jabs are potent agents for weight loss, they are not a standalone solution and lasting health benefits likely depends on combined behavioural support.